Endothelial progenitor cells and human diseases

Role of Resveratrol (RES) in Regenerative Medicine

Within the last quarter century, technology has been a major catalyst of the advancement in various fields of scientific knowledge, particularly medical research. This new enlightenment has spurred the exploration of alternative treatment methods to some of society's most problematic diseases. One such innovative treatment is the use of Resveratrol (RES) to treat a number of pathophysiological conditions. RES is a natural polyphenolic compound found in the skin(s) of blueberries, red grapes (a major constituent of red wine), some vegetables, and even peanuts. The compound has a number of potent regenerative properties, which include: anti-aging, anti-inflammatory, and antioxidative. Research has confirmed both in vivo and in vitro RES's beneficial applications to numerous diseases. This chapter centers on its unique healing powers and beneficial applications against myriad debilitating conditions.

Severe Type 2 Diabetes Induces Reversible Modifications of Endothelial Progenitor Cells Which are Ameliorate by Glycemic Control

Background

Circulating endothelial progenitors cells (EPCs) play a critical role in neovascularization and endothelial repair. There is a growing evidence that hyperglycemia related to Diabetes Mellitus (DM) decreases EPC number and function so promoting vascular complications.

Aim of the Study

This study investigated whether an intensive glycemic control regimen in Type 2 DM can increase the number of EPCs and restores their function.

Methods

Sixty-two patients with Type 2 DM were studied. Patients were tested at baseline and after 3 months of an intensive regimen of glycemic control. The Type 2 DM group was compared to control group of subjects without diabetes. Patients with Type 2 DM (mean age 58.2±5.4 years, 25.6% women, disease duration of 15.4±6.3 years) had a baseline HgA1c of 8.7±0.5% and lower EPC levels (CD34+/KDR+) in comparison to healthy controls (p<0.01).

Results

The intensive glycemic control regimen (HgA1c decreased to 6.2±0.3%) was coupled with a significant increase of EPC levels (mean of 18%, p<0.04 vs. baseline) and number of EPCs CFUs (p<0.05 vs. baseline).

Conclusion

This study confirms that number and bioactivity of EPCs are reduced in patients with Type 2 DM and, most importantly, that the intensive glycemic control in Type 2 DM promotes EPC improvement both in their number and in bioactivity.